改善重症社区获得性肺炎患者的诊疗:药师驱动的诊断管理 bundle
结果显示 bundle 组病原体检出率和抗菌药物降阶梯率显著提高,且未对患者安全结局产生负面影响,但抗菌药物疗程无差异。
要点
- 药师驱动的诊断管理 bundle 可提高 CAP 患者病原体检出率(51% vs 34%)。
- 该干预使抗菌药物降阶梯率从 26% 提升至 58%,且不增加死亡、再治疗或再入院风险。
- 干预未缩短抗菌药物中位疗程(均为 7 天)或 ICU 住院时间。
核心结论
- 实施药师驱动的肺炎诊断管理 bundle 提高了基于证据的诊断检测使用率和病原体检出率。
- 该干预与抗菌药物降阶梯频率增加相关,且未对患者安全结局产生负面影响。
研究设计与样本
- 干预措施为建立住院患者协作实践协议,授权 MICU 药师根据标准开具 CAP 诊断检测。
主要发现
- CPA 组病原体检出率显著高于 SOC 组(46 例 [51%] vs 31 例 [34%],p=0.035)。
- CPA 组抗菌药物降阶梯率显著高于 SOC 组(53 例 [58%] vs 24 例 [26%],p<0.001)。
- 两组抗菌药物中位疗程均为 7 天(SOC 组 IQR 6-10,CPA 组 IQR 6-8),无差异。
- 两组 ICU 住院时间中位数分别为 SOC 组 4 天(IQR 2-10)和 CPA 组 6 天(IQR 3-10),无显著差异。
- 两组住院全因死亡率(13 例 [14%] vs 7 例 [8%])、再治疗(14 例 [15%] vs 11 例 [12%])和 30 天再入院率(16 例 [18%] vs 13 例 [14%])均无显著差异。
临床怎么用
- 在 MICU 中可通过协作实践协议授权药师根据标准开具 CAP 诊断检测,以促进病原学诊断和抗菌药物降阶梯。
局限性
- 研究为单中心前后对照设计,样本量有限,结果可能受时间趋势等混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to improve antimicrobial management and outcomes of critically ill patients with community-acquired pneumonia (CAP) through implementation of a pharmacist-driven bundle for ordering evidence-based diagnostic tests in a medical intensive care unit (MICU). METHODS: An inpatient collaborative practice agreement (CPA) was established for MICU pharmacists to order criteria-driven diagnostic testing for CAP from November 2017-March 2018. Adults admitted to the MICU and started on empiric antibiotics for CAP were included. The intervention arm was compared with a standard of care (SOC) group from November 2016-March 2017. RESULTS: Ninety-one patients were included in each group. There was no difference in the median antibiotic duration between SOC and CPA, at 7 days (interquartile range [IQR], 6-10) versus 7 days (IQR, 6-8), respectively. The overall use of evidence-based diagnostic tests increased in the CPA group. Patients in the CPA group had more frequent pathogen identification (SOC and CPA, respectively: 31 [34%] versus 46 [51%], p = 0.035) and antimicrobial deescalation (24 [26%] versus 53 [58%], p < 0.001). There was no significant difference in length of intensive care unit stay, at 4 days for SOC (IQR, 2-10) versus 6 days for CPA (IQR, 3-10), and no significant difference in inpatient all-cause mortality (13 [14%] versus 7 [8%]), retreatment 14 [15%] versus 11 [12%]), or 30-day readmission 16 ([18%] versus 13 [14%]) for SOC and CPA, respectively. The CPA was the only variable that was independently associated with antimicrobial deescalation (odds ratio, 4.030; 95% confidence interval, 2.101-7.731) in a multiple logistic regression. CONCLUSION: Implementation of a pharmacy-driven pneumonia diagnostic stewardship bundle improved the use of evidence-based diagnostics and increased the frequency of pathogen identification. This intervention was associated with increased antimicrobial deescalation without a negative impact on patient safety outcomes.
引用
- Bianchini ML, Mercuro NJ, Kenney RM, et al. Improving care for critically ill patients with community-acquired pneumonia. Am J Health Syst Pharm. 2019. PMID: 31361849. doi:10.1093/ajhp/zxz068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。